The company said that life science segment net sales for the quarter were $334.2 million, an increase of 32.6% compared to the same quarter in 2020. Clinical diagnostics segment sales meanwhile were $380.2 million, an increase of 34.3% compared to the same period last year.

Overall net sales for the quarter were $715.9 million, an increase of 33.4% compared to $536.9 million reported for the second quarter of 2020.

Company leaders said the performance for both areas was ahead of expectations.

10x Genomics inks license deal with Bio-Rad
10x Genomics and Bio-Rad Laboratories have settled their legal dispute and signed a global settlement and cross-license agreement.

Bio-Rad launches new StarBright dyes for flow cytometry
Bio-Rad Laboratories has unveiled three new StarBright dyes geared toward flow cytometry applications.

Bio-Rad reports 1st quarter gains
Bio-Rad Laboratories on Thursday announced financial results for its first quarter.

Bio-Rad's sales rise in Q4, full fiscal year
Bio-Rad Laboratories announced a jump in sales for its fourth quarter and full fiscal year due to increased demand for COVID-19 assays.

Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed...